AR128130A2 - Métodos para evaluar conveniencia de un filtro bioquímico - Google Patents
Métodos para evaluar conveniencia de un filtro bioquímicoInfo
- Publication number
- AR128130A2 AR128130A2 ARP220103612A ARP220103612A AR128130A2 AR 128130 A2 AR128130 A2 AR 128130A2 AR P220103612 A ARP220103612 A AR P220103612A AR P220103612 A ARP220103612 A AR P220103612A AR 128130 A2 AR128130 A2 AR 128130A2
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- filters
- biochemical filter
- evaluate suitability
- endotoxins
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000002158 endotoxin Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000004886 process control Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D24/00—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof
- B01D24/02—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof with the filter bed stationary during the filtration
- B01D24/10—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof with the filter bed stationary during the filtration the filtering material being held in a closed container
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M37/00—Means for sterilizing, maintaining sterile conditions or avoiding chemical or biological contamination
- C12M37/02—Filters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/579—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving limulus lysate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Sustainable Development (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Realizaciones de la presente revelación incluyen métodos y sistemas para detectar la presencia de endotoxinas en filtros. Por ejemplo, realizaciones de la presente revelación se dirigen a métodos y sistemas para mejorar controles en procesos mediante detección de cantidades no deseadas de endotoxinas en filtros que contienen materiales que provienen de fuentes que se dan naturalmente previo a usar aquellos filtros en la producción de sustancias farmacéuticas formuladas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862665721P | 2018-05-02 | 2018-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR128130A2 true AR128130A2 (es) | 2024-03-27 |
Family
ID=67106126
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101127A AR114848A1 (es) | 2018-05-02 | 2019-04-29 | Métodos para evaluar conveniencia de un filtro bioquímico |
ARP220103612A AR128130A2 (es) | 2018-05-02 | 2022-12-27 | Métodos para evaluar conveniencia de un filtro bioquímico |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101127A AR114848A1 (es) | 2018-05-02 | 2019-04-29 | Métodos para evaluar conveniencia de un filtro bioquímico |
Country Status (7)
Country | Link |
---|---|
US (2) | US11378571B2 (es) |
EP (1) | EP3787766A1 (es) |
CN (2) | CN112020384B (es) |
AR (2) | AR114848A1 (es) |
CA (1) | CA3097903A1 (es) |
TW (2) | TWI814812B (es) |
WO (1) | WO2019212881A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114602237B (zh) * | 2022-03-10 | 2023-11-28 | 华兰生物工程股份有限公司 | 一种从人血浆或人血浆衍生原料中去除内毒素的方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPM388494A0 (en) * | 1994-02-16 | 1994-03-10 | Csl Limited | Process for removing endotoxins |
DE69623196T3 (de) * | 1995-06-30 | 2019-11-21 | Toray Industries, Inc. | Permselektive Membranen und Verfahren zu ihrer Herstellung |
US6953686B1 (en) * | 1999-05-28 | 2005-10-11 | Cambrex Bio Science Baltimore, Inc. | Methods of DNA purification and purified DNA |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
WO2002063271A2 (en) * | 2001-02-05 | 2002-08-15 | Activx Biosciences, Inc. | Activity based probe analysis |
WO2002083710A2 (en) * | 2001-04-13 | 2002-10-24 | Wyeth Holdings Corporation | Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography |
EP1402014A1 (en) * | 2001-06-29 | 2004-03-31 | Hemebiotech A/S | A process for purification of recombinant porphobilinogen deaminase |
FR2840992B1 (fr) * | 2002-06-18 | 2004-09-03 | Hemosystem | Procede de denombrement et/ou d'identification morphologique de leucocytes en phase solide |
WO2006088650A2 (en) | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
KR101406811B1 (ko) | 2006-06-16 | 2014-06-12 | 리제너론 파마슈티칼스 인코포레이티드 | 유리체내 투여에 적당한 vegf 길항제 제형 |
KR101523111B1 (ko) * | 2007-02-28 | 2015-06-25 | 리폭센 테크놀로지즈 리미티드 | 폴리시알산의 내독소 감소 |
EP2153260B1 (en) * | 2007-05-23 | 2017-01-25 | VGXI, Inc. | Composition comprising high concentration of biologically active molecules and processes for preparing the same |
DE102008037678A1 (de) * | 2008-08-14 | 2010-02-25 | Sartorius Stedim Biotech Gmbh | Tiefenfilterschicht mit anorganischem Schichtdoppelhydroxid |
KR101843915B1 (ko) * | 2008-08-14 | 2018-04-02 | 제넨테크, 인크. | 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법 |
US8277649B2 (en) * | 2009-12-14 | 2012-10-02 | General Electric Company | Membranes and associated methods for purification of antibodies |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
US8941405B2 (en) | 2012-08-03 | 2015-01-27 | International Business Machines Corporation | FET pair based physically unclonable function (PUF) circuit with a constant common mode voltage |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
WO2015031899A1 (en) * | 2013-08-30 | 2015-03-05 | Emd Millipore Corporation | High capacity composite depth filter media with low extractables |
WO2016089886A2 (en) | 2014-12-02 | 2016-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for treating dry eye disease by administering an il-6r antagonist |
CN105251049B (zh) * | 2015-09-29 | 2018-04-10 | 浙江星月生物科技股份有限公司 | 一种去除生物医用材料中细菌内毒素的离子缓冲液及应用 |
-
2019
- 2019-04-17 TW TW108113294A patent/TWI814812B/zh active
- 2019-04-17 TW TW112131975A patent/TW202348297A/zh unknown
- 2019-04-26 EP EP19734173.8A patent/EP3787766A1/en active Pending
- 2019-04-26 CA CA3097903A patent/CA3097903A1/en active Pending
- 2019-04-26 CN CN201980028426.9A patent/CN112020384B/zh active Active
- 2019-04-26 CN CN202310153482.3A patent/CN116212464A/zh active Pending
- 2019-04-26 US US16/395,431 patent/US11378571B2/en active Active
- 2019-04-26 WO PCT/US2019/029268 patent/WO2019212881A1/en unknown
- 2019-04-29 AR ARP190101127A patent/AR114848A1/es active IP Right Grant
-
2022
- 2022-05-26 US US17/804,222 patent/US20220404335A1/en active Pending
- 2022-12-27 AR ARP220103612A patent/AR128130A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN112020384B (zh) | 2023-03-10 |
TWI814812B (zh) | 2023-09-11 |
EP3787766A1 (en) | 2021-03-10 |
US20220404335A1 (en) | 2022-12-22 |
US20190339254A1 (en) | 2019-11-07 |
AR114848A1 (es) | 2020-10-21 |
CN116212464A (zh) | 2023-06-06 |
CA3097903A1 (en) | 2019-11-07 |
TW201946687A (zh) | 2019-12-16 |
TW202348297A (zh) | 2023-12-16 |
CN112020384A (zh) | 2020-12-01 |
US11378571B2 (en) | 2022-07-05 |
WO2019212881A1 (en) | 2019-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018003326A2 (pt) | anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos | |
CO2018002446A2 (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
BR112017001212A2 (pt) | processamento de biomassa | |
CL2019001517A1 (es) | Anticuerpos y métodos de su utilización. | |
AR128130A2 (es) | Métodos para evaluar conveniencia de un filtro bioquímico | |
CL2017003195A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso. | |
CU20150104A7 (es) | Método de separación de sólidos de líquidos de un lodo que comprende biomasa | |
MX2017007766A (es) | Material no tejido, metodo para fabricar el mismo y articulos que incorporan el material no tejido. | |
CR20180225A (es) | Anticuerpo anti-tigit y métodos de uso | |
MX2016014752A (es) | Procedimiento de separacion de material residual. | |
MX2023005724A (es) | Materiales polimericos de ciclodextrina con carga y metodos para su fabricacion y uso. | |
EA201692157A1 (ru) | Синтез двухцепочечных нуклеиновых кислот | |
BR112017026558B8 (pt) | Cartucho para a separação de uma mistura de fluidos, módulo de separação de fluidos e método para a separação de uma mistura composta por pelo menos dois fluidos | |
UA111729C2 (uk) | Пристрій для відокремлення твердих речовин від рідини і спосіб обробки біомаси, який включає відокремлення твердих речовин від рідини | |
AR119393A1 (es) | Anticuerpos que se unen a nkg2d | |
UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
AU2018274704A1 (en) | Assay for plasma cell associated disease | |
EA202190795A1 (ru) | Способ деполимеризации пластикового материала для производства углеводородов и установка для этого способа | |
PL439807A1 (pl) | Sposoby oczyszczania przeciwciał i ich kompozycje | |
BR112017003122A2 (pt) | materiais zeolíticos com acentuada macroposididade no monocristal e processo para a sua produção | |
CL2016000999A1 (es) | Anticuerpos anti-cd38 específicos para tratar cánceres humanos | |
WO2018208135A3 (ko) | 미세구조물을 이용한 세포 및 세포 생성물의 분리, 획득, 분석 및 회수 방법 | |
CO2021005178A2 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
BR112017015298B8 (pt) | Processo para a decomposição de material de biomassa contendo lignocelulose | |
MX2022003691A (es) | Espectrometria de masas nativa acoplada a cromatografia de interaccion hidrofobica para analisis de anticuerpos. |